FRISS
29.10.2020 07:58:08 CET | Business Wire | Press release
Grupo Ageas Portugal, serving approximately 1.7 million clients with 1,281 employees and via 2,722 agents, announced today that they have selected FRISS Fraud Detection at Claims in order to streamline their digital claim handling and prevent and protect their customers from fraud.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005826/en/
The real-time FRISS solution provides a unique combination of out-of-the-box risk and fraud indicators with powerful AI techniques such as predictive models, network analysis, and text mining. With this flexible and future-proof claims fraud solution, Grupo Ageas Portugal will further drive its digital transformation and safely streamline operations. Its customers can be helped with service beyond insurance, while high risks will be automatically flagged for further investigation.
The FRISS solution is pre-integrated with Duck Creek Claims . In order to provide a seamless experience for their claim adjusters, Grupo Ageas Portugal will be using the Anywhere Enabled Integration for this solution available in Duck Creek’s Content Exchange . Besides delivering fast customer service for the insurer’s clients, this will also limit the amount of false positives, giving employees time to focus on their customers. This is a great example of a technology-driven partnership in innovation.
Sjoerd Smeets, Chief Risk Officer at Grupo Ageas, said: "With the choice of FRISS, we have opted for a company fully dedicated to fraud prevention. During the selection process, they have shown their industry knowledge, good technical solutions, and especially agility. We are confident that with FRISS we will detect more fraud, handle claims faster, and provide higher quality for our customers."
Ariane Braam-Verkoren, Global Alliance Manager at FRISS, added, “In my journey at FRISS to expand our business to many new territories in the world, I’m excited to see so many insurers join our quest for honest insurance. We are proud to have Grupo Ageas on board and to be their partner of choice in the fight against fraud in Portugal.”
“To offer the best in risk and fraud detection to our customers, it was critical for us to align with a partner like FRISS,” said Juan Antonio Costa, Country Manager for Spain & Portugal at Duck Creek Technologies. “Their solution employs ultra-modern technologies like machine learning and AI, and Grupo Ageas Portugal made an excellent choice for their customers and for the efficiency of their organization by rapidly executing this step in their digital transformation.”
FRISS Fraud Detection at Claims will be implemented at Grupo Ageas Portugal’s Motor, Property, WMC (Workers’ Compensation), and Personal Accidents lines of business.
About Grupo Ageas Portugal
Founded in 1824, Ageas is an international insurance group based in Brussels and present in 14 countries in Europe and Asia. Operating in Portugal since 2005, Ageas invests in the country as one of the main markets, where it intends to develop, through strong partnerships and contributing to the development of the country and society through the Ageas Foundation and helping Clients to manage, anticipate and protect yourself against risks and unforeseen circumstances, so that you can live the present and the future with maximum security and serenity. The Ageas Portugal Group's mission is to provide an emotional and relevant experience in people's lives, being a reference partner in insurance and the best workplace for entrepreneurial people. To this end, we have 1,281 Employees and 2,722 Mediators to provide an excellent service to the approximately 1.7 million Customers of the various commercial brands: Ageas Seguros, Ageas Pensões, Médis, Ocidental and Seguro Directo. In order to diversify the business and be close to its customers, the Ageas Portugal Group goes beyond insurance, offering a wide range of services through the Clínica Médis, Kleya, Go Far, Ageas Repara and Mundo Ageas. For more information, you can visit the website , or follow us on Linkedin and Instagram .
About Duck Creek Technologies:
Duck Creek Technologies is a leading provider of core system solutions to the P&C and General insurance industry. By accessing Duck Creek OnDemand , the company’s enterprise Software-as-a-Service solution, insurance carriers are able to navigate uncertainty and capture market opportunities faster than their competitors. Duck Creek’s functionally rich solutions are available on a stand-alone basis or as a full suite , and all are available via Duck Creek OnDemand. For more information, visit www.duckcreek.com .
About FRISS
FRISS is 100% focused on automated fraud and risk detection for P&C insurance companies worldwide. Their AI-powered detection solutions for underwriting, claims and SIU help 175+ insurers grow their business. FRISS detects fraud, mitigates risks and supports digital transformation. Insurers go live within 4 months, realize up to 10 times ROI and 80% increase in straight through processing of policy application and claims. FRISS solutions help lower loss ratios, enable profitable portfolio growth, and improve the customer experience. For more information, please visit www.friss.com or Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005826/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom